nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—SLC6A3—malignant glioma	0.643	1	CbGaD
Nefazodone—HTR2C—choroid plexus—malignant glioma	0.0183	0.164	CbGeAlD
Nefazodone—HTR2A—choroid plexus—malignant glioma	0.00919	0.0822	CbGeAlD
Nefazodone—SLC6A3—telencephalic ventricle—malignant glioma	0.00555	0.0496	CbGeAlD
Nefazodone—Tonic-clonic seizures—Carmustine—malignant glioma	0.00552	0.034	CcSEcCtD
Nefazodone—HTR2C—telencephalic ventricle—malignant glioma	0.00537	0.048	CbGeAlD
Nefazodone—HTR2A—cerebellar cortex—malignant glioma	0.00463	0.0414	CbGeAlD
Nefazodone—HTR1A—telencephalic ventricle—malignant glioma	0.00452	0.0404	CbGeAlD
Nefazodone—Hyperacusis—Temozolomide—malignant glioma	0.00386	0.0238	CcSEcCtD
Nefazodone—Paranoid reaction—Carmustine—malignant glioma	0.0035	0.0215	CcSEcCtD
Nefazodone—HTR2A—pons—malignant glioma	0.00327	0.0293	CbGeAlD
Nefazodone—HTR2A—vertebral column—malignant glioma	0.00325	0.029	CbGeAlD
Nefazodone—Grand mal convulsion—Carmustine—malignant glioma	0.00313	0.0192	CcSEcCtD
Nefazodone—HTR2A—telencephalic ventricle—malignant glioma	0.00269	0.0241	CbGeAlD
Nefazodone—Trifluoperazine—CALY—malignant glioma	0.00263	0.57	CrCbGaD
Nefazodone—Oral candidiasis—Carmustine—malignant glioma	0.00234	0.0144	CcSEcCtD
Nefazodone—HTR2A—pineal body—malignant glioma	0.00234	0.0209	CbGeAlD
Nefazodone—Oral candidiasis—Temozolomide—malignant glioma	0.00226	0.0139	CcSEcCtD
Nefazodone—Tooth disorder—Temozolomide—malignant glioma	0.00222	0.0136	CcSEcCtD
Nefazodone—Paranoia—Carmustine—malignant glioma	0.00218	0.0134	CcSEcCtD
Nefazodone—Apathy—Temozolomide—malignant glioma	0.00201	0.0124	CcSEcCtD
Nefazodone—Flat affect—Temozolomide—malignant glioma	0.00199	0.0123	CcSEcCtD
Nefazodone—Scotoma—Carmustine—malignant glioma	0.00196	0.0121	CcSEcCtD
Nefazodone—Scotoma—Temozolomide—malignant glioma	0.00189	0.0117	CcSEcCtD
Nefazodone—Memory impairment—Temozolomide—malignant glioma	0.00183	0.0113	CcSEcCtD
Nefazodone—Hyperaesthesia—Temozolomide—malignant glioma	0.00183	0.0113	CcSEcCtD
Nefazodone—Accidental injury—Carmustine—malignant glioma	0.00168	0.0104	CcSEcCtD
Nefazodone—Breast pain—Temozolomide—malignant glioma	0.00165	0.0101	CcSEcCtD
Nefazodone—Thinking abnormal—Carmustine—malignant glioma	0.00163	0.01	CcSEcCtD
Nefazodone—Gait disturbance—Carmustine—malignant glioma	0.00152	0.00939	CcSEcCtD
Nefazodone—Coordination abnormal—Carmustine—malignant glioma	0.00152	0.00933	CcSEcCtD
Nefazodone—Neck pain—Carmustine—malignant glioma	0.00151	0.00927	CcSEcCtD
Nefazodone—SLC6A3—brainstem—malignant glioma	0.0015	0.0134	CbGeAlD
Nefazodone—Gait disturbance—Temozolomide—malignant glioma	0.00147	0.00907	CcSEcCtD
Nefazodone—Coordination abnormal—Temozolomide—malignant glioma	0.00146	0.00901	CcSEcCtD
Nefazodone—HTR2C—brainstem—malignant glioma	0.00145	0.013	CbGeAlD
Nefazodone—HTR2A—endothelium—malignant glioma	0.00145	0.0129	CbGeAlD
Nefazodone—Vaginal inflammation—Temozolomide—malignant glioma	0.00144	0.00885	CcSEcCtD
Nefazodone—Urinary incontinence—Carmustine—malignant glioma	0.00144	0.00885	CcSEcCtD
Nefazodone—Candida infection—Carmustine—malignant glioma	0.00142	0.00875	CcSEcCtD
Nefazodone—Urinary incontinence—Temozolomide—malignant glioma	0.00139	0.00855	CcSEcCtD
Nefazodone—SLC6A4—brainstem—malignant glioma	0.00138	0.0123	CbGeAlD
Nefazodone—Candida infection—Temozolomide—malignant glioma	0.00137	0.00845	CcSEcCtD
Nefazodone—Vaginal infection—Temozolomide—malignant glioma	0.00136	0.00836	CcSEcCtD
Nefazodone—SLC6A3—telencephalon—malignant glioma	0.00133	0.0119	CbGeAlD
Nefazodone—HTR2A—blood vessel—malignant glioma	0.00133	0.0119	CbGeAlD
Nefazodone—Gynaecomastia—Carmustine—malignant glioma	0.00133	0.0082	CcSEcCtD
Nefazodone—Dry eye—Temozolomide—malignant glioma	0.00133	0.00818	CcSEcCtD
Nefazodone—Abnormal vision—Carmustine—malignant glioma	0.0013	0.00799	CcSEcCtD
Nefazodone—Mental disability—Carmustine—malignant glioma	0.00129	0.00795	CcSEcCtD
Nefazodone—HTR2C—telencephalon—malignant glioma	0.00129	0.0115	CbGeAlD
Nefazodone—Abnormal vision—Temozolomide—malignant glioma	0.00125	0.00772	CcSEcCtD
Nefazodone—Mental disability—Temozolomide—malignant glioma	0.00125	0.00768	CcSEcCtD
Nefazodone—Ear pain—Temozolomide—malignant glioma	0.00122	0.00753	CcSEcCtD
Nefazodone—HTR1A—brainstem—malignant glioma	0.00122	0.0109	CbGeAlD
Nefazodone—SLC6A4—telencephalon—malignant glioma	0.00122	0.0109	CbGeAlD
Nefazodone—SLC6A2—brainstem—malignant glioma	0.00121	0.0108	CbGeAlD
Nefazodone—Eye pain—Carmustine—malignant glioma	0.0012	0.00737	CcSEcCtD
Nefazodone—Gastroenteritis—Temozolomide—malignant glioma	0.00118	0.00725	CcSEcCtD
Nefazodone—Injury—Carmustine—malignant glioma	0.00118	0.00723	CcSEcCtD
Nefazodone—Deafness—Temozolomide—malignant glioma	0.00117	0.00718	CcSEcCtD
Nefazodone—Hepatic failure—Temozolomide—malignant glioma	0.00116	0.00715	CcSEcCtD
Nefazodone—Eye pain—Temozolomide—malignant glioma	0.00116	0.00712	CcSEcCtD
Nefazodone—ADRA1A—brainstem—malignant glioma	0.00113	0.0101	CbGeAlD
Nefazodone—Thirst—Temozolomide—malignant glioma	0.0011	0.00675	CcSEcCtD
Nefazodone—HTR1A—telencephalon—malignant glioma	0.00109	0.0097	CbGeAlD
Nefazodone—Hyponatraemia—Carmustine—malignant glioma	0.00108	0.00668	CcSEcCtD
Nefazodone—Diplopia—Carmustine—malignant glioma	0.00108	0.00665	CcSEcCtD
Nefazodone—Gastrointestinal haemorrhage—Carmustine—malignant glioma	0.00108	0.00665	CcSEcCtD
Nefazodone—SLC6A2—telencephalon—malignant glioma	0.00108	0.00962	CbGeAlD
Nefazodone—Diplopia—Temozolomide—malignant glioma	0.00104	0.00643	CcSEcCtD
Nefazodone—Face oedema—Carmustine—malignant glioma	0.00104	0.00642	CcSEcCtD
Nefazodone—Affect lability—Temozolomide—malignant glioma	0.00103	0.00632	CcSEcCtD
Nefazodone—Ataxia—Carmustine—malignant glioma	0.00102	0.00625	CcSEcCtD
Nefazodone—HTR2C—medulla oblongata—malignant glioma	0.00101	0.00905	CbGeAlD
Nefazodone—ADRA1B—central nervous system—malignant glioma	0.00101	0.00905	CbGeAlD
Nefazodone—Face oedema—Temozolomide—malignant glioma	0.00101	0.0062	CcSEcCtD
Nefazodone—ADRA1A—telencephalon—malignant glioma	0.001	0.00894	CbGeAlD
Nefazodone—Liver function test abnormal—Carmustine—malignant glioma	0.000997	0.00614	CcSEcCtD
Nefazodone—Mood swings—Temozolomide—malignant glioma	0.000989	0.00609	CcSEcCtD
Nefazodone—Ataxia—Temozolomide—malignant glioma	0.000981	0.00604	CcSEcCtD
Nefazodone—Dehydration—Temozolomide—malignant glioma	0.000971	0.00598	CcSEcCtD
Nefazodone—SLC6A3—midbrain—malignant glioma	0.000958	0.00856	CbGeAlD
Nefazodone—Dry skin—Temozolomide—malignant glioma	0.000957	0.00589	CcSEcCtD
Nefazodone—Aspartate aminotransferase increased—Temozolomide—malignant glioma	0.00094	0.00579	CcSEcCtD
Nefazodone—SLC6A3—spinal cord—malignant glioma	0.000935	0.00835	CbGeAlD
Nefazodone—Dysphagia—Carmustine—malignant glioma	0.000934	0.00575	CcSEcCtD
Nefazodone—HTR2C—midbrain—malignant glioma	0.000926	0.00827	CbGeAlD
Nefazodone—Domperidone—CYP2B6—malignant glioma	0.000923	0.2	CrCbGaD
Nefazodone—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.000921	0.00567	CcSEcCtD
Nefazodone—Abdominal distension—Temozolomide—malignant glioma	0.000908	0.00559	CcSEcCtD
Nefazodone—HTR2C—spinal cord—malignant glioma	0.000903	0.00807	CbGeAlD
Nefazodone—Dysphagia—Temozolomide—malignant glioma	0.000902	0.00555	CcSEcCtD
Nefazodone—SLC6A4—midbrain—malignant glioma	0.000878	0.00784	CbGeAlD
Nefazodone—ABCB1—blood vessel—malignant glioma	0.000874	0.00781	CbGeAlD
Nefazodone—Bronchitis—Temozolomide—malignant glioma	0.000868	0.00534	CcSEcCtD
Nefazodone—SLC6A4—spinal cord—malignant glioma	0.000856	0.00765	CbGeAlD
Nefazodone—SLC6A2—medulla oblongata—malignant glioma	0.000846	0.00756	CbGeAlD
Nefazodone—Dysuria—Temozolomide—malignant glioma	0.000844	0.00519	CcSEcCtD
Nefazodone—Pneumonia—Carmustine—malignant glioma	0.000837	0.00515	CcSEcCtD
Nefazodone—Pollakiuria—Temozolomide—malignant glioma	0.000833	0.00513	CcSEcCtD
Nefazodone—Erectile dysfunction—Temozolomide—malignant glioma	0.000831	0.00512	CcSEcCtD
Nefazodone—Photosensitivity reaction—Temozolomide—malignant glioma	0.000823	0.00507	CcSEcCtD
Nefazodone—Weight increased—Temozolomide—malignant glioma	0.000821	0.00505	CcSEcCtD
Nefazodone—Weight decreased—Temozolomide—malignant glioma	0.000816	0.00502	CcSEcCtD
Nefazodone—Stomatitis—Carmustine—malignant glioma	0.000811	0.00499	CcSEcCtD
Nefazodone—Urinary tract infection—Carmustine—malignant glioma	0.000809	0.00498	CcSEcCtD
Nefazodone—Pneumonia—Temozolomide—malignant glioma	0.000809	0.00498	CcSEcCtD
Nefazodone—ADRA1B—brain—malignant glioma	0.000804	0.00718	CbGeAlD
Nefazodone—Stevens-Johnson syndrome—Temozolomide—malignant glioma	0.000797	0.00491	CcSEcCtD
Nefazodone—HTR2A—embryo—malignant glioma	0.000795	0.00711	CbGeAlD
Nefazodone—Stomatitis—Temozolomide—malignant glioma	0.000784	0.00483	CcSEcCtD
Nefazodone—Urinary tract infection—Temozolomide—malignant glioma	0.000782	0.00481	CcSEcCtD
Nefazodone—HTR1A—midbrain—malignant glioma	0.000779	0.00697	CbGeAlD
Nefazodone—ADRA2A—telencephalon—malignant glioma	0.000761	0.0068	CbGeAlD
Nefazodone—HTR1A—spinal cord—malignant glioma	0.00076	0.0068	CbGeAlD
Nefazodone—SLC6A3—central nervous system—malignant glioma	0.000758	0.00678	CbGeAlD
Nefazodone—Sinusitis—Temozolomide—malignant glioma	0.000755	0.00465	CcSEcCtD
Nefazodone—Haemoglobin—Carmustine—malignant glioma	0.000751	0.00462	CcSEcCtD
Nefazodone—Haemorrhage—Carmustine—malignant glioma	0.000747	0.0046	CcSEcCtD
Nefazodone—Hypoaesthesia—Carmustine—malignant glioma	0.000743	0.00458	CcSEcCtD
Nefazodone—Hallucination—Carmustine—malignant glioma	0.000743	0.00458	CcSEcCtD
Nefazodone—SLC6A3—cerebellum—malignant glioma	0.000741	0.00662	CbGeAlD
Nefazodone—Oedema peripheral—Carmustine—malignant glioma	0.000736	0.00453	CcSEcCtD
Nefazodone—HTR2C—central nervous system—malignant glioma	0.000733	0.00655	CbGeAlD
Nefazodone—HTR2A—brainstem—malignant glioma	0.000729	0.00651	CbGeAlD
Nefazodone—Haemoglobin—Temozolomide—malignant glioma	0.000726	0.00447	CcSEcCtD
Nefazodone—Haemorrhage—Temozolomide—malignant glioma	0.000722	0.00445	CcSEcCtD
Nefazodone—Hepatitis—Temozolomide—malignant glioma	0.000722	0.00445	CcSEcCtD
Nefazodone—Visual impairment—Carmustine—malignant glioma	0.00072	0.00443	CcSEcCtD
Nefazodone—Hallucination—Temozolomide—malignant glioma	0.000718	0.00442	CcSEcCtD
Nefazodone—Hypoaesthesia—Temozolomide—malignant glioma	0.000718	0.00442	CcSEcCtD
Nefazodone—Pharyngitis—Temozolomide—malignant glioma	0.000717	0.00441	CcSEcCtD
Nefazodone—Oedema peripheral—Temozolomide—malignant glioma	0.000711	0.00438	CcSEcCtD
Nefazodone—HTR2A—retina—malignant glioma	0.000703	0.00628	CbGeAlD
Nefazodone—Visual impairment—Temozolomide—malignant glioma	0.000696	0.00428	CcSEcCtD
Nefazodone—SLC6A4—central nervous system—malignant glioma	0.000695	0.00621	CbGeAlD
Nefazodone—Flushing—Carmustine—malignant glioma	0.000693	0.00427	CcSEcCtD
Nefazodone—Erythema multiforme—Temozolomide—malignant glioma	0.000683	0.0042	CcSEcCtD
Nefazodone—Tinnitus—Temozolomide—malignant glioma	0.000673	0.00414	CcSEcCtD
Nefazodone—Flushing—Temozolomide—malignant glioma	0.00067	0.00413	CcSEcCtD
Nefazodone—CYP2D6—brainstem—malignant glioma	0.000664	0.00593	CbGeAlD
Nefazodone—Alopecia—Carmustine—malignant glioma	0.00066	0.00406	CcSEcCtD
Nefazodone—Chills—Temozolomide—malignant glioma	0.000648	0.00399	CcSEcCtD
Nefazodone—HTR2A—telencephalon—malignant glioma	0.000647	0.00578	CbGeAlD
Nefazodone—Alopecia—Temozolomide—malignant glioma	0.000638	0.00393	CcSEcCtD
Nefazodone—Back pain—Carmustine—malignant glioma	0.000629	0.00387	CcSEcCtD
Nefazodone—HTR1A—central nervous system—malignant glioma	0.000617	0.00551	CbGeAlD
Nefazodone—Dysgeusia—Temozolomide—malignant glioma	0.000616	0.00379	CcSEcCtD
Nefazodone—Vision blurred—Carmustine—malignant glioma	0.000613	0.00377	CcSEcCtD
Nefazodone—Perphenazine—CYP2C18—malignant glioma	0.000612	0.132	CrCbGaD
Nefazodone—SLC6A2—central nervous system—malignant glioma	0.000612	0.00547	CbGeAlD
Nefazodone—Tremor—Carmustine—malignant glioma	0.000609	0.00375	CcSEcCtD
Nefazodone—Back pain—Temozolomide—malignant glioma	0.000608	0.00374	CcSEcCtD
Nefazodone—HTR1A—cerebellum—malignant glioma	0.000603	0.00539	CbGeAlD
Nefazodone—SLC6A3—brain—malignant glioma	0.000602	0.00538	CbGeAlD
Nefazodone—Anaemia—Carmustine—malignant glioma	0.000601	0.0037	CcSEcCtD
Nefazodone—Agitation—Carmustine—malignant glioma	0.000598	0.00368	CcSEcCtD
Nefazodone—ADRA2A—medulla oblongata—malignant glioma	0.000598	0.00534	CbGeAlD
Nefazodone—Vision blurred—Temozolomide—malignant glioma	0.000592	0.00365	CcSEcCtD
Nefazodone—CYP2D6—telencephalon—malignant glioma	0.000589	0.00527	CbGeAlD
Nefazodone—Tremor—Temozolomide—malignant glioma	0.000589	0.00363	CcSEcCtD
Nefazodone—Ill-defined disorder—Temozolomide—malignant glioma	0.000583	0.00359	CcSEcCtD
Nefazodone—Leukopenia—Carmustine—malignant glioma	0.000582	0.00358	CcSEcCtD
Nefazodone—HTR2C—brain—malignant glioma	0.000582	0.0052	CbGeAlD
Nefazodone—Anaemia—Temozolomide—malignant glioma	0.000581	0.00358	CcSEcCtD
Nefazodone—Agitation—Temozolomide—malignant glioma	0.000578	0.00356	CcSEcCtD
Nefazodone—Angioedema—Temozolomide—malignant glioma	0.000574	0.00354	CcSEcCtD
Nefazodone—ADRA1A—central nervous system—malignant glioma	0.000569	0.00508	CbGeAlD
Nefazodone—Malaise—Temozolomide—malignant glioma	0.000567	0.00349	CcSEcCtD
Nefazodone—Vertigo—Temozolomide—malignant glioma	0.000565	0.00348	CcSEcCtD
Nefazodone—Convulsion—Carmustine—malignant glioma	0.000564	0.00347	CcSEcCtD
Nefazodone—Leukopenia—Temozolomide—malignant glioma	0.000563	0.00346	CcSEcCtD
Nefazodone—Hypertension—Carmustine—malignant glioma	0.000562	0.00346	CcSEcCtD
Nefazodone—ADRA1A—cerebellum—malignant glioma	0.000556	0.00497	CbGeAlD
Nefazodone—Palpitations—Temozolomide—malignant glioma	0.000555	0.00342	CcSEcCtD
Nefazodone—Chest pain—Carmustine—malignant glioma	0.000554	0.00341	CcSEcCtD
Nefazodone—Myalgia—Carmustine—malignant glioma	0.000554	0.00341	CcSEcCtD
Nefazodone—Anxiety—Carmustine—malignant glioma	0.000552	0.0034	CcSEcCtD
Nefazodone—SLC6A4—brain—malignant glioma	0.000552	0.00493	CbGeAlD
Nefazodone—Cough—Temozolomide—malignant glioma	0.000549	0.00338	CcSEcCtD
Nefazodone—ADRA2A—midbrain—malignant glioma	0.000546	0.00488	CbGeAlD
Nefazodone—Convulsion—Temozolomide—malignant glioma	0.000545	0.00335	CcSEcCtD
Nefazodone—Hypertension—Temozolomide—malignant glioma	0.000543	0.00334	CcSEcCtD
Nefazodone—Confusional state—Carmustine—malignant glioma	0.000535	0.0033	CcSEcCtD
Nefazodone—Arthralgia—Temozolomide—malignant glioma	0.000535	0.00329	CcSEcCtD
Nefazodone—Myalgia—Temozolomide—malignant glioma	0.000535	0.00329	CcSEcCtD
Nefazodone—Anxiety—Temozolomide—malignant glioma	0.000533	0.00328	CcSEcCtD
Nefazodone—ADRA2A—spinal cord—malignant glioma	0.000533	0.00476	CbGeAlD
Nefazodone—Oedema—Carmustine—malignant glioma	0.000531	0.00327	CcSEcCtD
Nefazodone—Discomfort—Temozolomide—malignant glioma	0.000529	0.00326	CcSEcCtD
Nefazodone—Infection—Carmustine—malignant glioma	0.000527	0.00325	CcSEcCtD
Nefazodone—Dry mouth—Temozolomide—malignant glioma	0.000523	0.00322	CcSEcCtD
Nefazodone—ABCB1—embryo—malignant glioma	0.000521	0.00466	CbGeAlD
Nefazodone—Thrombocytopenia—Carmustine—malignant glioma	0.00052	0.0032	CcSEcCtD
Nefazodone—Tachycardia—Carmustine—malignant glioma	0.000518	0.00319	CcSEcCtD
Nefazodone—Confusional state—Temozolomide—malignant glioma	0.000517	0.00318	CcSEcCtD
Nefazodone—Oedema—Temozolomide—malignant glioma	0.000513	0.00316	CcSEcCtD
Nefazodone—Anaphylactic shock—Temozolomide—malignant glioma	0.000513	0.00316	CcSEcCtD
Nefazodone—Infection—Temozolomide—malignant glioma	0.00051	0.00314	CcSEcCtD
Nefazodone—HTR2A—medulla oblongata—malignant glioma	0.000508	0.00454	CbGeAlD
Nefazodone—Anorexia—Carmustine—malignant glioma	0.000506	0.00312	CcSEcCtD
Nefazodone—Thrombocytopenia—Temozolomide—malignant glioma	0.000502	0.00309	CcSEcCtD
Nefazodone—Hypotension—Carmustine—malignant glioma	0.000496	0.00305	CcSEcCtD
Nefazodone—Hyperhidrosis—Temozolomide—malignant glioma	0.000496	0.00305	CcSEcCtD
Nefazodone—HTR1A—brain—malignant glioma	0.00049	0.00438	CbGeAlD
Nefazodone—Anorexia—Temozolomide—malignant glioma	0.000489	0.00301	CcSEcCtD
Nefazodone—SLC6A2—brain—malignant glioma	0.000486	0.00434	CbGeAlD
Nefazodone—Musculoskeletal discomfort—Carmustine—malignant glioma	0.000484	0.00298	CcSEcCtD
Nefazodone—Insomnia—Carmustine—malignant glioma	0.00048	0.00296	CcSEcCtD
Nefazodone—Paraesthesia—Carmustine—malignant glioma	0.000477	0.00293	CcSEcCtD
Nefazodone—Dyspnoea—Carmustine—malignant glioma	0.000473	0.00291	CcSEcCtD
Nefazodone—Somnolence—Carmustine—malignant glioma	0.000472	0.00291	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.000467	0.00288	CcSEcCtD
Nefazodone—HTR2A—midbrain—malignant glioma	0.000464	0.00415	CbGeAlD
Nefazodone—Insomnia—Temozolomide—malignant glioma	0.000464	0.00286	CcSEcCtD
Nefazodone—Decreased appetite—Carmustine—malignant glioma	0.000461	0.00284	CcSEcCtD
Nefazodone—ABCB1—retina—malignant glioma	0.000461	0.00412	CbGeAlD
Nefazodone—Paraesthesia—Temozolomide—malignant glioma	0.000461	0.00284	CcSEcCtD
Nefazodone—Dyspnoea—Temozolomide—malignant glioma	0.000457	0.00282	CcSEcCtD
Nefazodone—Somnolence—Temozolomide—malignant glioma	0.000456	0.00281	CcSEcCtD
Nefazodone—Perphenazine—CYP2B6—malignant glioma	0.000454	0.0983	CrCbGaD
Nefazodone—Constipation—Carmustine—malignant glioma	0.000454	0.00279	CcSEcCtD
Nefazodone—Pain—Carmustine—malignant glioma	0.000454	0.00279	CcSEcCtD
Nefazodone—HTR2A—spinal cord—malignant glioma	0.000453	0.00405	CbGeAlD
Nefazodone—Dyspepsia—Temozolomide—malignant glioma	0.000452	0.00278	CcSEcCtD
Nefazodone—ADRA1A—brain—malignant glioma	0.000451	0.00403	CbGeAlD
Nefazodone—Decreased appetite—Temozolomide—malignant glioma	0.000446	0.00275	CcSEcCtD
Nefazodone—Pain—Temozolomide—malignant glioma	0.000439	0.0027	CcSEcCtD
Nefazodone—Constipation—Temozolomide—malignant glioma	0.000439	0.0027	CcSEcCtD
Nefazodone—Feeling abnormal—Carmustine—malignant glioma	0.000437	0.00269	CcSEcCtD
Nefazodone—Gastrointestinal pain—Carmustine—malignant glioma	0.000434	0.00267	CcSEcCtD
Nefazodone—ADRA2A—central nervous system—malignant glioma	0.000432	0.00386	CbGeAlD
Nefazodone—ABCB1—telencephalon—malignant glioma	0.000424	0.00379	CbGeAlD
Nefazodone—Feeling abnormal—Temozolomide—malignant glioma	0.000423	0.0026	CcSEcCtD
Nefazodone—ADRA2A—cerebellum—malignant glioma	0.000423	0.00378	CbGeAlD
Nefazodone—Abdominal pain—Carmustine—malignant glioma	0.00042	0.00258	CcSEcCtD
Nefazodone—Body temperature increased—Carmustine—malignant glioma	0.00042	0.00258	CcSEcCtD
Nefazodone—Gastrointestinal pain—Temozolomide—malignant glioma	0.00042	0.00258	CcSEcCtD
Nefazodone—Urticaria—Temozolomide—malignant glioma	0.000408	0.00251	CcSEcCtD
Nefazodone—Abdominal pain—Temozolomide—malignant glioma	0.000406	0.0025	CcSEcCtD
Nefazodone—Body temperature increased—Temozolomide—malignant glioma	0.000406	0.0025	CcSEcCtD
Nefazodone—Hypersensitivity—Carmustine—malignant glioma	0.000391	0.00241	CcSEcCtD
Nefazodone—Asthenia—Carmustine—malignant glioma	0.000381	0.00234	CcSEcCtD
Nefazodone—Hypersensitivity—Temozolomide—malignant glioma	0.000378	0.00233	CcSEcCtD
Nefazodone—Asthenia—Temozolomide—malignant glioma	0.000368	0.00227	CcSEcCtD
Nefazodone—HTR2A—central nervous system—malignant glioma	0.000368	0.00329	CbGeAlD
Nefazodone—Diarrhoea—Carmustine—malignant glioma	0.000363	0.00224	CcSEcCtD
Nefazodone—Pruritus—Temozolomide—malignant glioma	0.000363	0.00223	CcSEcCtD
Nefazodone—HTR2A—cerebellum—malignant glioma	0.000359	0.00321	CbGeAlD
Nefazodone—Dizziness—Carmustine—malignant glioma	0.000351	0.00216	CcSEcCtD
Nefazodone—Diarrhoea—Temozolomide—malignant glioma	0.000351	0.00216	CcSEcCtD
Nefazodone—ADRA2A—brain—malignant glioma	0.000343	0.00307	CbGeAlD
Nefazodone—CYP3A4—central nervous system—malignant glioma	0.00034	0.00304	CbGeAlD
Nefazodone—Dizziness—Temozolomide—malignant glioma	0.000339	0.00209	CcSEcCtD
Nefazodone—Vomiting—Carmustine—malignant glioma	0.000338	0.00208	CcSEcCtD
Nefazodone—CYP2D6—central nervous system—malignant glioma	0.000335	0.00299	CbGeAlD
Nefazodone—Rash—Carmustine—malignant glioma	0.000335	0.00206	CcSEcCtD
Nefazodone—Dermatitis—Carmustine—malignant glioma	0.000334	0.00206	CcSEcCtD
Nefazodone—ABCB1—medulla oblongata—malignant glioma	0.000333	0.00298	CbGeAlD
Nefazodone—Headache—Carmustine—malignant glioma	0.000333	0.00205	CcSEcCtD
Nefazodone—CYP2D6—cerebellum—malignant glioma	0.000327	0.00293	CbGeAlD
Nefazodone—Vomiting—Temozolomide—malignant glioma	0.000326	0.00201	CcSEcCtD
Nefazodone—Rash—Temozolomide—malignant glioma	0.000323	0.00199	CcSEcCtD
Nefazodone—Dermatitis—Temozolomide—malignant glioma	0.000323	0.00199	CcSEcCtD
Nefazodone—Headache—Temozolomide—malignant glioma	0.000321	0.00198	CcSEcCtD
Nefazodone—Nausea—Carmustine—malignant glioma	0.000315	0.00194	CcSEcCtD
Nefazodone—Nausea—Temozolomide—malignant glioma	0.000305	0.00188	CcSEcCtD
Nefazodone—ABCB1—midbrain—malignant glioma	0.000304	0.00272	CbGeAlD
Nefazodone—ABCB1—spinal cord—malignant glioma	0.000297	0.00265	CbGeAlD
Nefazodone—HTR2A—brain—malignant glioma	0.000292	0.00261	CbGeAlD
Nefazodone—CYP2D6—brain—malignant glioma	0.000266	0.00238	CbGeAlD
Nefazodone—ABCB1—central nervous system—malignant glioma	0.000241	0.00215	CbGeAlD
Nefazodone—ABCB1—cerebellum—malignant glioma	0.000235	0.0021	CbGeAlD
Nefazodone—ABCB1—brain—malignant glioma	0.000191	0.00171	CbGeAlD
Nefazodone—CYP3A7—Metabolism—PIK3CB—malignant glioma	8.61e-06	0.00011	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—EGFR—malignant glioma	8.59e-06	0.00011	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PDGFB—malignant glioma	8.58e-06	0.00011	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—AKT2—malignant glioma	8.58e-06	0.00011	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PPARG—malignant glioma	8.55e-06	0.00011	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—EGFR—malignant glioma	8.54e-06	0.000109	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—FGFR1—malignant glioma	8.54e-06	0.000109	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PTGS2—malignant glioma	8.53e-06	0.000109	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—FN1—malignant glioma	8.51e-06	0.000109	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—F2—malignant glioma	8.51e-06	0.000109	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GSTP1—malignant glioma	8.46e-06	0.000108	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—BRAF—malignant glioma	8.44e-06	0.000108	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—HIF1A—malignant glioma	8.41e-06	0.000108	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—BAD—malignant glioma	8.41e-06	0.000108	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—AKT1—malignant glioma	8.34e-06	0.000107	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—FN1—malignant glioma	8.33e-06	0.000107	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—F2—malignant glioma	8.33e-06	0.000107	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—NOTCH1—malignant glioma	8.33e-06	0.000107	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PIK3CD—malignant glioma	8.29e-06	0.000106	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—NCOR1—malignant glioma	8.25e-06	0.000106	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PIK3CD—malignant glioma	8.24e-06	0.000106	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CAT—malignant glioma	8.23e-06	0.000105	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—BAD—malignant glioma	8.23e-06	0.000105	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—AKT2—malignant glioma	8.21e-06	0.000105	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—PIK3CA—malignant glioma	8.21e-06	0.000105	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—EGFR—malignant glioma	8.18e-06	0.000105	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—PIK3CA—malignant glioma	8.17e-06	0.000105	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CD80—malignant glioma	8.16e-06	0.000104	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—NOTCH1—malignant glioma	8.15e-06	0.000104	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—APC—malignant glioma	8.14e-06	0.000104	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PIK3CG—malignant glioma	8.14e-06	0.000104	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CAV1—malignant glioma	8.13e-06	0.000104	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PIK3CG—malignant glioma	8.12e-06	0.000104	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—KRAS—malignant glioma	8.11e-06	0.000104	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—KRAS—malignant glioma	8.07e-06	0.000103	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—EGF—malignant glioma	8.05e-06	0.000103	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—KDR—malignant glioma	8.04e-06	0.000103	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PTPN11—malignant glioma	8e-06	0.000102	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CD80—malignant glioma	7.99e-06	0.000102	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSTT1—malignant glioma	7.98e-06	0.000102	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PIK3CG—malignant glioma	7.97e-06	0.000102	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—APC—malignant glioma	7.97e-06	0.000102	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—FGF2—malignant glioma	7.93e-06	0.000102	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—FGF2—malignant glioma	7.89e-06	0.000101	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PIK3CD—malignant glioma	7.89e-06	0.000101	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—EGF—malignant glioma	7.88e-06	0.000101	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PPARG—malignant glioma	7.84e-06	0.0001	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PTPN11—malignant glioma	7.83e-06	0.0001	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—PIK3CA—malignant glioma	7.82e-06	0.0001	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PIK3CD—malignant glioma	7.79e-06	9.98e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—NCOR1—malignant glioma	7.78e-06	9.96e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—F2—malignant glioma	7.74e-06	9.92e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—FN1—malignant glioma	7.74e-06	9.92e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—KRAS—malignant glioma	7.73e-06	9.9e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—BRAF—malignant glioma	7.65e-06	9.8e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—BAD—malignant glioma	7.65e-06	9.8e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—NOTCH1—malignant glioma	7.58e-06	9.7e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—FGF2—malignant glioma	7.56e-06	9.68e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—BRAF—malignant glioma	7.49e-06	9.6e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTGS1—malignant glioma	7.48e-06	9.58e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—PIK3CA—malignant glioma	7.45e-06	9.55e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—AKT2—malignant glioma	7.45e-06	9.54e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PTEN—malignant glioma	7.44e-06	9.53e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MDM2—malignant glioma	7.42e-06	9.51e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CD80—malignant glioma	7.42e-06	9.51e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—EGFR—malignant glioma	7.42e-06	9.5e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—PIK3CA—malignant glioma	7.42e-06	9.5e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—APC—malignant glioma	7.41e-06	9.49e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PIK3CG—malignant glioma	7.41e-06	9.49e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—RAF1—malignant glioma	7.4e-06	9.48e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MDM2—malignant glioma	7.39e-06	9.46e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—RAF1—malignant glioma	7.36e-06	9.43e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—EGF—malignant glioma	7.32e-06	9.38e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—ERBB2—malignant glioma	7.32e-06	9.37e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—AKT2—malignant glioma	7.3e-06	9.34e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—ERBB2—malignant glioma	7.28e-06	9.33e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PTPN11—malignant glioma	7.28e-06	9.32e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—EGFR—malignant glioma	7.26e-06	9.3e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PIK3CB—malignant glioma	7.22e-06	9.25e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PIK3CB—malignant glioma	7.19e-06	9.2e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PIK3CD—malignant glioma	7.16e-06	9.17e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PIK3CD—malignant glioma	7.14e-06	9.14e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—PIK3CA—malignant glioma	7.1e-06	9.09e-05	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—PIK3CA—malignant glioma	7.09e-06	9.08e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MDM2—malignant glioma	7.07e-06	9.06e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—RAF1—malignant glioma	7.05e-06	9.02e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PIK3CD—malignant glioma	7.01e-06	8.98e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—KRAS—malignant glioma	7.01e-06	8.98e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—ERBB2—malignant glioma	6.97e-06	8.93e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—BRAF—malignant glioma	6.96e-06	8.92e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—BCHE—malignant glioma	6.95e-06	8.91e-05	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—PIK3CA—malignant glioma	6.94e-06	8.89e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CXCL8—malignant glioma	6.94e-06	8.89e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CXCL8—malignant glioma	6.91e-06	8.84e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PIK3CB—malignant glioma	6.88e-06	8.81e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—SLC5A5—malignant glioma	6.87e-06	8.8e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—KRAS—malignant glioma	6.86e-06	8.79e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—FGF2—malignant glioma	6.85e-06	8.78e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PIK3CB—malignant glioma	6.79e-06	8.7e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—AKT2—malignant glioma	6.78e-06	8.68e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—EGFR—malignant glioma	6.75e-06	8.65e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PTGS2—malignant glioma	6.73e-06	8.62e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CAV1—malignant glioma	6.73e-06	8.62e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—FGF2—malignant glioma	6.71e-06	8.6e-05	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—AKT1—malignant glioma	6.7e-06	8.59e-05	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—AKT1—malignant glioma	6.67e-06	8.54e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CASP3—malignant glioma	6.64e-06	8.51e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IL2—malignant glioma	6.63e-06	8.5e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CXCL8—malignant glioma	6.61e-06	8.47e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CASP3—malignant glioma	6.61e-06	8.47e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IL2—malignant glioma	6.6e-06	8.45e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PIK3CD—malignant glioma	6.51e-06	8.34e-05	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—PIK3CA—malignant glioma	6.45e-06	8.26e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—PIK3CA—malignant glioma	6.44e-06	8.25e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MDM2—malignant glioma	6.41e-06	8.21e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—RAF1—malignant glioma	6.39e-06	8.19e-05	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—AKT1—malignant glioma	6.39e-06	8.18e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—KRAS—malignant glioma	6.38e-06	8.17e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CAV1—malignant glioma	6.34e-06	8.12e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CASP3—malignant glioma	6.33e-06	8.1e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—ERBB2—malignant glioma	6.32e-06	8.1e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IL2—malignant glioma	6.32e-06	8.09e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—PIK3CA—malignant glioma	6.3e-06	8.08e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MDM2—malignant glioma	6.28e-06	8.04e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MMP9—malignant glioma	6.28e-06	8.04e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—RAF1—malignant glioma	6.26e-06	8.02e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MMP9—malignant glioma	6.25e-06	8e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PTEN—malignant glioma	6.24e-06	7.99e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PIK3CB—malignant glioma	6.24e-06	7.99e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—FGF2—malignant glioma	6.24e-06	7.99e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PIK3CB—malignant glioma	6.22e-06	7.97e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PTEN—malignant glioma	6.21e-06	7.95e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—ERBB2—malignant glioma	6.19e-06	7.93e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PTGS2—malignant glioma	6.16e-06	7.9e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CG—malignant glioma	6.13e-06	7.85e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PIK3CB—malignant glioma	6.11e-06	7.83e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—AKT1—malignant glioma	6.09e-06	7.8e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—AKT1—malignant glioma	6.06e-06	7.76e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CXCL8—malignant glioma	6e-06	7.68e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MMP9—malignant glioma	5.98e-06	7.66e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PTEN—malignant glioma	5.94e-06	7.61e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PPARG—malignant glioma	5.91e-06	7.57e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CXCL8—malignant glioma	5.87e-06	7.52e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PTEN—malignant glioma	5.87e-06	7.51e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—PIK3CA—malignant glioma	5.86e-06	7.5e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MDM2—malignant glioma	5.83e-06	7.47e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—RAF1—malignant glioma	5.81e-06	7.45e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—AKT1—malignant glioma	5.8e-06	7.43e-05	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—AKT1—malignant glioma	5.79e-06	7.42e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CG—malignant glioma	5.77e-06	7.4e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—ERBB2—malignant glioma	5.75e-06	7.37e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CASP3—malignant glioma	5.74e-06	7.35e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL2—malignant glioma	5.73e-06	7.34e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PIK3CB—malignant glioma	5.68e-06	7.27e-05	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—AKT1—malignant glioma	5.67e-06	7.26e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—VEGFA—malignant glioma	5.64e-06	7.22e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CASP3—malignant glioma	5.62e-06	7.2e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL2—malignant glioma	5.61e-06	7.19e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—VEGFA—malignant glioma	5.61e-06	7.18e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—STAT3—malignant glioma	5.58e-06	7.15e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PPARG—malignant glioma	5.57e-06	7.14e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—STAT3—malignant glioma	5.55e-06	7.11e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSTP1—malignant glioma	5.53e-06	7.09e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CXCL8—malignant glioma	5.46e-06	6.99e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MMP9—malignant glioma	5.42e-06	6.95e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PTEN—malignant glioma	5.39e-06	6.91e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CD—malignant glioma	5.39e-06	6.9e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CAT—malignant glioma	5.38e-06	6.89e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PTEN—malignant glioma	5.38e-06	6.89e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—VEGFA—malignant glioma	5.37e-06	6.88e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—STAT3—malignant glioma	5.32e-06	6.81e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MMP9—malignant glioma	5.31e-06	6.8e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PTEN—malignant glioma	5.28e-06	6.76e-05	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—AKT1—malignant glioma	5.27e-06	6.75e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—AKT1—malignant glioma	5.26e-06	6.74e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PIK3CA—malignant glioma	5.25e-06	6.72e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CASP3—malignant glioma	5.22e-06	6.69e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL2—malignant glioma	5.21e-06	6.68e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MYC—malignant glioma	5.19e-06	6.64e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MYC—malignant glioma	5.16e-06	6.61e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—AKT1—malignant glioma	5.15e-06	6.6e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—NCOR1—malignant glioma	5.08e-06	6.51e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CD—malignant glioma	5.08e-06	6.5e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—EGFR—malignant glioma	5.07e-06	6.5e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—EGFR—malignant glioma	5.05e-06	6.46e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MYC—malignant glioma	4.94e-06	6.33e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MMP9—malignant glioma	4.93e-06	6.32e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PTEN—malignant glioma	4.91e-06	6.28e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—VEGFA—malignant glioma	4.87e-06	6.24e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—EGFR—malignant glioma	4.83e-06	6.19e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—STAT3—malignant glioma	4.82e-06	6.18e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—KRAS—malignant glioma	4.79e-06	6.14e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—AKT1—malignant glioma	4.79e-06	6.13e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—VEGFA—malignant glioma	4.77e-06	6.11e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—KRAS—malignant glioma	4.77e-06	6.11e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—STAT3—malignant glioma	4.72e-06	6.05e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CB—malignant glioma	4.69e-06	6.01e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PTGS2—malignant glioma	4.65e-06	5.96e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—KRAS—malignant glioma	4.56e-06	5.85e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MYC—malignant glioma	4.48e-06	5.74e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—VEGFA—malignant glioma	4.43e-06	5.68e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CB—malignant glioma	4.42e-06	5.67e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PIK3CA—malignant glioma	4.4e-06	5.64e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MYC—malignant glioma	4.39e-06	5.62e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—STAT3—malignant glioma	4.39e-06	5.62e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PTGS2—malignant glioma	4.38e-06	5.61e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—EGFR—malignant glioma	4.38e-06	5.61e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PIK3CA—malignant glioma	4.38e-06	5.61e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—EGFR—malignant glioma	4.29e-06	5.5e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—AKT1—malignant glioma	4.29e-06	5.49e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TP53—malignant glioma	4.26e-06	5.46e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TP53—malignant glioma	4.24e-06	5.43e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PIK3CA—malignant glioma	4.19e-06	5.37e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CAV1—malignant glioma	4.14e-06	5.31e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—KRAS—malignant glioma	4.14e-06	5.3e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PIK3CA—malignant glioma	4.14e-06	5.3e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MYC—malignant glioma	4.08e-06	5.22e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PTEN—malignant glioma	4.06e-06	5.2e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TP53—malignant glioma	4.06e-06	5.2e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—KRAS—malignant glioma	4.05e-06	5.19e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—EGFR—malignant glioma	3.99e-06	5.11e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PTEN—malignant glioma	3.82e-06	4.9e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PIK3CA—malignant glioma	3.8e-06	4.87e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PIK3CA—malignant glioma	3.79e-06	4.86e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CG—malignant glioma	3.77e-06	4.83e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—KRAS—malignant glioma	3.77e-06	4.82e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PIK3CA—malignant glioma	3.72e-06	4.77e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TP53—malignant glioma	3.68e-06	4.71e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PPARG—malignant glioma	3.64e-06	4.67e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TP53—malignant glioma	3.6e-06	4.62e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—AKT1—malignant glioma	3.6e-06	4.61e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—AKT1—malignant glioma	3.58e-06	4.58e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PIK3CA—malignant glioma	3.46e-06	4.43e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—AKT1—malignant glioma	3.43e-06	4.39e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—AKT1—malignant glioma	3.38e-06	4.33e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TP53—malignant glioma	3.35e-06	4.29e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CD—malignant glioma	3.32e-06	4.25e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—AKT1—malignant glioma	3.11e-06	3.98e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—AKT1—malignant glioma	3.1e-06	3.97e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—AKT1—malignant glioma	3.04e-06	3.9e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CB—malignant glioma	2.89e-06	3.7e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTGS2—malignant glioma	2.87e-06	3.67e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CA—malignant glioma	2.86e-06	3.67e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—AKT1—malignant glioma	2.83e-06	3.62e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CA—malignant glioma	2.7e-06	3.45e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTEN—malignant glioma	2.5e-06	3.2e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—AKT1—malignant glioma	2.34e-06	2.99e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—AKT1—malignant glioma	2.2e-06	2.82e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CA—malignant glioma	1.76e-06	2.26e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—AKT1—malignant glioma	1.44e-06	1.84e-05	CbGpPWpGaD
